Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease

Burgel, Pierre-Régis;Paillasseur, Jean-Louis;Durieu, Isabelle;Reynaud-Gaubert, Martine;Tiotiu-Cepuc, Iuliana;et.al.
(2024) Annals of the American Thoracic Society — Vol. 21, n° 7, p. 1053-1064 (2024)

Files

Burgel.pdf
  • Open Access
  • Adobe PDF
  • 1.2 MB
Download

Details

Authors
  • Burgel, Pierre-RégisUniversité Paris Cité, Institut Cochin, INSERM U1016, Paris, France
    Author
  • Paillasseur, Jean-LouisEffi-Stat, Paris, France
    Author
  • Durieu, IsabelleCentre de Référence Adulte de la Mucoviscidose, Service de Médecine Interne, Hospices Civils de Lyon, Pierre Bénite, France
    Author
  • Reynaud-Gaubert, MartineDepartment of Respiratory Medicine and Lung Transplantation, Adult Cystic Fibrosis Center Aix Marseille University, Assistance Publique–Hôpitaux de Marseille, Hôpital Nord, Marseille, France
    Author
  • Tiotiu-Cepuc, IulianaUCLouvain
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Burgel, P.-R., Paillasseur, J.-L., Durieu, I., Reynaud-Gaubert, M., Hamidfar, R., Murris-Espin, M., Danner-Boucher, I., Chiron, R., Leroy, S., Douvry, B., Grenet, D., Mely, L., Ramel, S., Montcouquiol, S., Burnet, E., Ouaalaya, E. H., Sogni, P., Da Silva, J., Martin, C., & Tiotiu-Cepuc, I. (2024). Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease. Annals of the American Thoracic Society, 21(7), 1053-1064. https://doi.org/10.1513/AnnalsATS.202312-1065OC (Original work published 2024)